Größte bisherige Fusionen der Pharmaindustrie
June 8, 2020 -
Der britisch-schwedische Konzern AstraZeneca, Co-Entwickler einer experimentellen Coronavirus Vakzine, lotet einen Zusammenschluss mit dem US Konkurrenten Gilead Sciences aus. Es wäre die größte Fusion in der Pharmaindustrie laut einem Bericht von Bloomberg.
Gilead was worth $96 billion at Friday’s close, while AstraZeneca has a market value of about $140 billion. A potential deal between two of the most prominent players in the coronavirus pandemic could create a behemoth amongst big pharma with a market value of nearly $240 billion.
California-based Gilead is one of the most successful makers of antiviral drugs. It’s remdesivir drug received emergency approval from the U.S. Food and Drug Administration in May as a coronavirus treatment.
AstraZeneca has an impressive pipeline of drugs in oncology, cardiovascular and respiratory disease. Meanwhile, the Cambridge-based company is collaborating with Oxford University’s Jenner Institute and the Oxford Vaccine Group to develop a recombinant adenovirus vaccine. The so-called AZD1222 vaccine began phase I and II clinical trials in April to assess safety, immunogenicity and efficacy in over 1,000 healthy volunteers in the UK.
While a merger could unite the two companies in their fight against coronavirus, uncertainty caused by the pandemic has dampened enthusiasm for mega-mergers, according to some city analysts.
Graphic News Standards